96 related articles for article (PubMed ID: 16637783)
21. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
[TBL] [Abstract][Full Text] [Related]
22. Increasing apoA-I production as a target for CHD risk reduction.
Dullens SP; Plat J; Mensink RP
Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):616-28. PubMed ID: 17703927
[TBL] [Abstract][Full Text] [Related]
23. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
24. The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care.
Lender D; Sysko SK
Pharmacotherapy; 2006 May; 26(5 Pt 2):3S-12S. PubMed ID: 16637782
[TBL] [Abstract][Full Text] [Related]
25. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk.
Smith SR
Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
Jones PH
Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
[TBL] [Abstract][Full Text] [Related]
27. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
28. Antiatherogenic small, dense HDL--guardian angel of the arterial wall?
Kontush A; Chapman MJ
Nat Clin Pract Cardiovasc Med; 2006 Mar; 3(3):144-53. PubMed ID: 16505860
[TBL] [Abstract][Full Text] [Related]
29. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
[TBL] [Abstract][Full Text] [Related]
30. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care].
Scholze J; Lilienthal W; Bramlage P
MMW Fortschr Med; 2007 Sep; 149 Suppl 3():103-10. PubMed ID: 17955787
[TBL] [Abstract][Full Text] [Related]
31. Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women.
Onat A; Hergenç G; Karabulut A; Albayrak S; Can G; Kaya Z
Metabolism; 2007 Oct; 56(10):1356-62. PubMed ID: 17884445
[TBL] [Abstract][Full Text] [Related]
32. 4-Hydroxyisoleucine: a plant-derived treatment for metabolic syndrome.
Jetté L; Harvey L; Eugeni K; Levens N
Curr Opin Investig Drugs; 2009 Apr; 10(4):353-8. PubMed ID: 19337956
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo.
Watts GF; Ooi EM; Chan DC
Pharmacol Ther; 2009 Sep; 123(3):281-91. PubMed ID: 19490928
[TBL] [Abstract][Full Text] [Related]
34. Effects of pioglitazone on lipid and lipoprotein metabolism.
Betteridge DJ
Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057
[TBL] [Abstract][Full Text] [Related]
35. Partial peroxisome proliferator-activated receptor agonist angiotensin receptor blockers. Potential multipronged strategy in stroke prevention.
Towfighi A; Ovbiagele B
Cerebrovasc Dis; 2008; 26(2):106-12. PubMed ID: 18560212
[TBL] [Abstract][Full Text] [Related]
36. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
[TBL] [Abstract][Full Text] [Related]
37. Hypertension and CHD risk: whither alpha-1 blockers?
Pandit RB
Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
[TBL] [Abstract][Full Text] [Related]
38. [Therapeutic options for metabolic syndrome in obese patients].
Carella AM; Conte M
Clin Ter; 2007; 158(5):457-64. PubMed ID: 18062354
[TBL] [Abstract][Full Text] [Related]
39. Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines.
Correia ML; Haynes WG
Expert Opin Emerg Drugs; 2005 Aug; 10(3):643-60. PubMed ID: 16083333
[TBL] [Abstract][Full Text] [Related]
40. Negative effects of risk factor reduction on the heart.
Alcocer L; Reyes AJ
Cardiol Clin; 1986 Feb; 4(1):153-61. PubMed ID: 2871932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
